
Vera Marisa Costa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2620059/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events. Archives of Toxicology, 2022, 96, 11-78.	4.2	9
2	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncology, The, 2022, 23, 27-52.	10.7	90
3	Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes. Archives of Toxicology, 2022, 96, 653-671.	4.2	14
4	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health, The, 2022, 7, e105-e125.	10.0	1,199
5	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. JAMA Oncology, 2022, 8, 420.	7.1	719
6	Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice. Archives of Toxicology, 2022, 96, 1767-1782.	4.2	6
7	Mitoxantrone-induced neurotoxicity in CD-1 mice. , 2022, 4, .	0.0	0
8	Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Gastroenterology and Hepatology, 2022, 7, 627-647.	8.1	177
9	Molecular alterations underlying Doxorubicin's Chronic Cardiotoxicity in a mouse model. , 2022, 4, .	0.0	0
10	Antidotal effect of cyclosporine A against α-amanitin toxicity in CD-1 mice, at clinical relevant doses. Food and Chemical Toxicology, 2022, 166, 113198.	3.6	5
11	Flavonoids as antiobesity agents: A review. Medicinal Research Reviews, 2021, 41, 556-585.	10.5	81
12	In vivo toxicometabolomics reveals multi-organ and urine metabolic changes in mice upon acuteÂexposure to human-relevant doses of 3,4-methylenedioxypyrovalerone (MDPV). Archives of Toxicology, 2021, 95, 509-527.	4.2	11
13	Discovery of New Potent Positive Allosteric Modulators of Dopamine D ₂ Receptors: Insights into the Bioisosteric Replacement of Proline to 3-Furoic Acid in the Melanostatin Neuropeptide. Journal of Medicinal Chemistry, 2021, 64, 6209-6220.	6.4	6
14	Inflammation as a Possible Trigger for Mitoxantrone-Induced Cardiotoxicity: An In Vivo Study in Adult and Infant Mice. Pharmaceuticals, 2021, 14, 510.	3.8	13
15	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet Public Health, The, 2021, 6, e482-e499.	10.0	38
16	An updated review on synthetic cathinones. Archives of Toxicology, 2021, 95, 2895-2940.	4.2	59
17	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet, The, 2021, 397, 2337-2360.	13.7	609
18	Exploring the aging effect of the anticancer drugs doxorubicin and mitoxantrone on cardiac mitochondrial proteome using a murine model. Toxicology, 2021, 459, 152852.	4.2	15

#	Article	IF	CITATIONS
19	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. Lancet, The, 2021, 398, 503-521.	13.7	93
20	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 870-905.	13.7	229
21	An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sciences, 2021, 280, 119760.	4.3	23
22	Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurology, The, 2021, 20, 795-820.	10.2	2,308
23	Chemobrain. , 2021, , 61-72.		0
24	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nature Medicine, 2021, 27, 1761-1782.	30.7	60
25	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	13.7	92
26	Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease study 2019. BMJ Global Health, 2021, 6, e004128.	4.7	41
27	Role of Inflammation and Redox Status on Doxorubicin-Induced Cardiotoxicity in Infant and Adult CD-1 Male Mice. Biomolecules, 2021, 11, 1725.	4.0	16
28	The Secretome of Human Neonatal Mesenchymal Stem Cells Modulates Doxorubicin-Induced Cytotoxicity: Impact in Non-Tumor Cells. International Journal of Molecular Sciences, 2021, 22, 13072.	4.1	7
29	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 42-54.	8.1	390
30	Clobal burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Clobal Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
31	Clobal burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Clobal Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
32	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	13.7	890
33	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
34	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. The Lancet Global Health, 2020, 8, e1038-e1060.	6.3	23
35	Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study. Injury Prevention, 2020, 26, i125-i153.	2.4	44
36	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330

#	Article	IF	CITATIONS
37	Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations. Archives of Toxicology, 2020, 94, 4067-4084.	4.2	9
38	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. The Lancet Global Health, 2020, 8, e1162-e1185.	6.3	91
39	Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i96-i114.	2.4	103
40	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 2020, 76, 2982-3021.	2.8	4,468
41	Adverse outcome pathways induced by 3,4-dimethylmethcathinone and 4-methylmethcathinone in differentiated human SH-SY5Y neuronal cells. Archives of Toxicology, 2020, 94, 2481-2503.	4.2	8
42	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72
43	In vitro mechanistic studies on α-amanitin and its putative antidotes. Archives of Toxicology, 2020, 94, 2061-2078.	4.2	20
44	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	8.1	823
45	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 582-597.	8.1	241
46	Methods for the analysis of transcriptome dynamics. Toxicology Research, 2019, 8, 597-612.	2.1	6
47	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncology, The, 2019, 20, 1211-1225.	10.7	199
48	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	27.8	161
49	Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells. NeuroToxicology, 2019, 75, 158-173.	3.0	25
50	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
51	The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. Biomolecules, 2019, 9, 98.	4.0	11
52	An effective antidotal combination of polymyxin B and methylprednisolone for α-amanitin intoxication. Archives of Toxicology, 2019, 93, 1449-1463.	4.2	22
53	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
54	Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells. Biomolecules, 2019, 9, 21.	4.0	13

#	Article	IF	CITATIONS
55	Histological and toxicological evaluation, in rat, of a P-glycoprotein inducer and activator: 1-(propan-2-ylamino)-4-propoxy-9-thioxanthen-9-one (TX5). EXCLI Journal, 2019, 18, 697-722.	0.7	2
56	Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats. Biomedicine and Pharmacotherapy, 2018, 100, 551-563.	5.6	9
57	Comprehensive review of cardiovascular toxicity of drugs and related agents. Medicinal Research Reviews, 2018, 38, 1332-1403.	10.5	176
58	Clorgyline and N-acetyl-L-cysteine provide partial protection against the toxicity of synthetic cathinones and methamphetamine on SH-SY5Y humans cells. Toxicology Letters, 2018, 295, S274.	0.8	1
59	Mitoxantrone is More Toxic than Doxorubicin in SH-SY5Y Human Cells: A â€~Chemobrain' In Vitro Study. Pharmaceuticals, 2018, 11, 41.	3.8	13
60	Aged rats are more vulnerable than adolescents to "ecstasy―induced toxicity. Archives of Toxicology, 2018, 92, 2275-2295.	4.2	9
61	Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells. Interdisciplinary Toxicology, 2018, 11, 13-21.	1.0	6
62	Toxicity of the amphetamine metabolites 4-hydroxyamphetamine and 4-hydroxynorephedrine in human dopaminergic differentiated SH-SY5Y cells. Toxicology Letters, 2017, 269, 65-76.	0.8	13
63	Quantitative histochemistry for macrophage biodistribution on mice liver and spleen after the administration of a pharmacological-relevant dose of polyacrylic acid-coated iron oxide nanoparticles. Nanotoxicology, 2017, 11, 256-266.	3.0	15
64	The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metabolism Reviews, 2017, 49, 158-196.	3.6	25
65	Methylphenidate effects in the young brain: friend or foe?. International Journal of Developmental Neuroscience, 2017, 60, 34-47.	1.6	22
66	Studies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone. Porto Biomedical Journal, 2017, 2, 220-221.	1.0	0
67	Chemical characterization and protective effect of the Bactris setosa Mart. fruit against oxidative/nitrosative stress. Food Chemistry, 2017, 220, 427-437.	8.2	26
68	Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Archives of Toxicology, 2017, 91, 1871-1890.	4.2	18
69	Biodistribution of polyacrylic acidâ€coated iron oxide nanoparticles is associated with proinflammatory activation and liver toxicity. Journal of Applied Toxicology, 2016, 36, 1321-1331.	2.8	29
70	"Ecstasy―toxicity to adolescent rats following an acute low binge dose. BMC Pharmacology & Toxicology, 2016, 17, 28.	2.4	10
71	The putative pro-inflammatory effect and oxidative stress induced by polyacrylic acid-coated iron oxide nanoparticles in mice: An biodistribution and toxicological study. Toxicology Letters, 2015, 238, S273.	0.8	0
72	Neurotoxicity of amphetamine and its metabolite 4-hydroxynorephedrine on differentiated SH-SY5Y dopaminergic cells. Toxicology Letters, 2015, 238, S358.	0.8	1

#	Article	IF	CITATIONS
73	The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity. Current Drug Metabolism, 2015, 17, 75-90.	1.2	41
74	The age factor for mitoxantrone's cardiotoxicity: Multiple doses render the adult mouse heart more susceptible to injury. Toxicology, 2015, 329, 106-119.	4.2	30
75	Quantification of alpha-amanitin in biological samples by HPLC using simultaneous UV- diode array and electrochemical detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 997, 85-95.	2.3	36
76	Co-ingestion of amatoxins and isoxazoles-containing mushrooms and successful treatment: A case report. Toxicon, 2015, 103, 55-59.	1.6	14
77	A breakthrough on Amanita phalloides poisoning: an effective antidotal effect by polymyxin B. Archives of Toxicology, 2015, 89, 2305-2323.	4.2	48
78	Amanita phalloides poisoning: Mechanisms of toxicity and treatment. Food and Chemical Toxicology, 2015, 86, 41-55.	3.6	145
79	The neurotoxicity of amphetamines during the adolescent period. International Journal of Developmental Neuroscience, 2015, 41, 44-62.	1.6	66
80	Inosine Strongly Enhances Proliferation of Human C32 Melanoma Cells through <scp>PLC</scp> â€ <scp>PKC</scp> â€< scp>MEK1/2â€< scp>ERK1/2 and PI3K Pathways. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 25-36.	2.5	21
81	Mitochondrial Cumulative Damage Induced by Mitoxantrone: Late Onset Cardiac Energetic Impairment. Cardiovascular Toxicology, 2014, 14, 30-40.	2.7	37
82	Combination of Cl-IB-MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR-dependent autophagy and mitotic catastrophe on human melanoma cells. Journal of Cancer Research and Clinical Oncology, 2014, 140, 921-935.	2.5	16
83	Cumulative Mitoxantroneâ€Induced Haematological and Hepatic Adverse Effects in a Subchronic <i>In vivo</i> Study. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 254-262.	2.5	13
84	Modeling chronic brain exposure to amphetamines using primary rat neuronal cortical cultures. Neuroscience, 2014, 277, 417-434.	2.3	7
85	The combination of Cl-IB-MECA with paclitaxel: a new anti-metastatic therapeutic strategy for melanoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 847-860.	2.3	10
86	The Heart As a Target for Xenobiotic Toxicity: The Cardiac Susceptibility to Oxidative Stress. Chemical Research in Toxicology, 2013, 26, 1285-1311.	3.3	70
87	Potentiation of cytotoxicity of paclitaxel in combination with Cl-IB-MECA in human C32 metastatic melanoma cells: A new possible therapeutic strategy for melanoma. Biomedicine and Pharmacotherapy, 2013, 67, 777-789.	5.6	14
88	Therapeutic Concentrations of Mitoxantrone Elicit Energetic Imbalance in H9c2 Cells as an Earlier Event. Cardiovascular Toxicology, 2013, 13, 413-425.	2.7	31
89	Neurotoxicity of "ecstasy―and its metabolites in human dopaminergic differentiated SH-SY5Y cells. Toxicology Letters, 2013, 216, 159-170.	0.8	39
90	The neurotoxicity of hallucinogenic amphetamines in primary cultures of hippocampal neurons. NeuroToxicology, 2013, 34, 254-263.	3.0	37

#	Article	IF	CITATIONS
91	â€~Ecstasy' and amphetamine neurotoxicity to cultured rat cortical neurons in a continuous exposure model. Toxicology Letters, 2013, 221, S233.	0.8	0
92	The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Archives of Toxicology, 2013, 87, 1809-1820.	4.2	49
93	Acetaminophen prevents oxidative burst and delays apoptosis in human neutrophils. Toxicology Letters, 2013, 219, 170-177.	0.8	17
94	Toxicity of amphetamines: an update. Archives of Toxicology, 2012, 86, 1167-1231.	4.2	364
95	Synephrine: From trace concentrations to massive consumption in weight-loss. Food and Chemical Toxicology, 2011, 49, 8-16.	3.6	95
96	Therapeutic concentrations of mitoxantrone elicit cytotoxic effects on H9c2 cells. Toxicology Letters, 2011, 205, S56.	0.8	0
97	â€~Ecstasy' and amphetamine induce developmental neurotoxicity to immature cultured rat cortical neurons. Toxicology Letters, 2011, 205, S113.	0.8	0
98	N-acetyl-cysteine prevents the cytotoxicity of adrenaline oxidation in SH-SY5Y cells. Toxicology Letters, 2011, 205, S220.	0.8	0
99	Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes. Archives of Toxicology, 2011, 85, 929-939.	4.2	27
100	Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases. Current Medicinal Chemistry, 2011, 18, 2272-2314.	2.4	93
101	Development and validation of a GC/IT-MS method for simultaneous quantitation of para and meta-synephrine in biological samples. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 721-726.	2.8	26
102	ER Stress-Inducible Factor CHOP Affects the Expression of Hepcidin by Modulating C/EBPalpha Activity. PLoS ONE, 2009, 4, e6618.	2.5	88
103	Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. Toxicology, 2009, 257, 70-79.	4.2	35
104	Adrenaline and reactive oxygen species elicit proteome and energetic metabolism modifications in freshly isolated rat cardiomyocytes. Toxicology, 2009, 260, 84-96.	4.2	30
105	Cross-Functioning between the Extraneuronal Monoamine Transporter and Multidrug Resistance Protein 1 in the Uptake of Adrenaline and Export of 5-(Glutathion <i>-S-</i> yl)adrenaline in Rat Cardiomyocytes. Chemical Research in Toxicology, 2009, 22, 129-135.	3.3	16
106	Oxidation Process of Adrenaline in Freshly Isolated Rat Cardiomyocytes: Formation of Adrenochrome, Quinoproteins, and GSH Adduct. Chemical Research in Toxicology, 2007, 20, 1183-1191.	3.3	68
107	Time dependent activation of transcription factors in freshly isolated cardiomyocytes: Adrenaline and reactive oxygen species incubation. Toxicology Letters, 2007, 172, S5-S6.	0.8	0
108	Evaluation of GSH adducts of adrenaline in biological samples. Biomedical Chromatography, 2007, 21, 670-679.	1.7	12

#	Article	IF	CITATIONS
109	Effect of adrenaline and oxygen free radicals on calcium tolerant cardiomyocytes: Formation of glutathione adducts. Toxicology Letters, 2006, 164, S130-S131.	0.8	ο
110	Validation of a HPLC-ECD method for the detection of adrenaline-GSH adducts in biological samples. Toxicology Letters, 2006, 164, S132.	0.8	0
111	Effects of Doxorubicin and Mitoxantrone in the brain of differently aged mice: in vivo chemobrain study. , 0, , .		0
112	The main products of cyclophosphamide bioactivation exert a cardiotoxic effect at clinical important concentrations in AC16 cardiac cells. , 0, , .		0
113	Anticancer drugs-induced toxicity in different age male CD-1 mice. , 0, , .		Ο
114	In vitro toxicity of $\hat{l}\pm$ -amanitin in human kidney cells and evaluation of protective effect of polymyxin B. , 0, , .		0